Business
Edesa Biotech, Inc.: Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects.
Net income decreased 16.5% to ($7.2M), while Operating cash flow decreased 49.7% to ($7.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($7.2M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 8 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Edesa Biotech, Inc.'s own filings, the day they're filed.
- Peter J. Weiler · Chief Financial Officer · appointmenteff. 2025-05-01
- Stephen Lemieux · Chief Financial Officer · departureeff. 2025-05-01
- David Liu · Directors · appointmenteff. 2025-02-12
Latest filings
- 8-K · Company announcement2026-08-20
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Edesa Biotech, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.